Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Rhea-AI Summary

Nutriband Inc. (NTRB) reported strong Q1 2025 financial results, achieving record revenue of $667,000, marking a 63% year-over-year increase. The growth is driven by expanded kinesiology tape production through Pocono Pharma subsidiary, with products now available in major retailers including Target, Walmart, Walgreens, and CVS. The company announced a significant partnership with Kindeva Drug Delivery for AVERSA Fentanyl development, featuring shared development costs and milestone payments. AVERSA Fentanyl aims to be the first abuse-deterrent opioid patch, with potential peak annual US sales estimated between $80-200 million. The product is designed to prevent abuse, misuse, and accidental exposure of transdermal fentanyl patches.

Positive

• Record Q1 revenue of $667,000, up 63% year-over-year
• Expanded retail presence in major chains (Target, Walmart, Walgreens, CVS)
• Strategic partnership with Kindeva Drug Delivery including milestone payments
• AVERSA Fentanyl potential peak annual US sales of $80-200 million

Negative

• Development costs sharing required with Kindeva Drug Delivery
• Penetration pricing strategy may impact margins
• Regulatory approval for AVERSA Fentanyl still pending

ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025.

Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry’s largest brands. The Company produced a record first quarter reporting revenue of $667,000USD, up 63% % YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS and the increasing Pocono revenue stream is key to the company’s focus on shareholder value.

Progress continues on the development of AVERSA Fentanyl, with the Company formalizing an exclusive product development partnership with Kindeva Drug Delivery. The formalized partnership with Kindeva Drug Delivery reflects a commitment to shared development costs in exchange for milestone payments, enabling Nutriband to advance its innovative transdermal drug delivery solutions towards regulatory approval and commercialization.

AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.¹

¹ Health Advances Aversa Fentanyl market analysis report 2022

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the year ended January, 2025, filed April 28, 2025, the Forms 10-Q’s filed subsequent to the Form 10-K in 2025, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

FAQ

What was Nutriband's (NTRB) revenue growth in Q1 2025?

Nutriband reported record Q1 2025 revenue of $667,000, representing a 63% increase year-over-year.

Where are Nutriband's Pocono manufactured products being sold?

Pocono manufactured products are being sold nationwide in major retail chains including Target, Walmart, Walgreens, and CVS.

What is AVERSA Fentanyl's market potential?

According to Health Advances market analysis, AVERSA Fentanyl has potential peak annual US sales of $80 million to $200 million.

Who is Nutriband's development partner for AVERSA Fentanyl?

Nutriband has formed an exclusive product development partnership with Kindeva Drug Delivery, sharing development costs in exchange for milestone payments.

What is unique about AVERSA Fentanyl?

AVERSA Fentanyl aims to be the world's first abuse-deterrent opioid patch, designed to deter abuse and misuse while reducing accidental exposure risks of transdermal fentanyl patches.